Drug intelligence / Profile preview

ZZ-1002

Development stage: Unknown
Lead developer: Zhongze Therapeutics
Modality: Small Molecules

Overview

ZZ-1002 is a small molecule drug initially developed by Zhongze Therapeutics Hong Kong Ltd. It is currently in the discovery phase of research and development, with its primary therapeutic area being schizophrenia. There are no reported clinical trials or regulatory approvals for this compound as of the latest available data. The specific mechanism of action, molecular target, and detailed pharmacological properties have not been disclosed publicly[1][2].

Other names: ZZ1002ZZ-1002ZZ 1002

Beyond the preview

Go deeper on ZZ-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZZ-1002.

Explore the full profile